July 15 (Reuters) - Hong Kong-listed Sino Biopharmaceutical 1177.HK said on Tuesday it will buy the remaining 95.09% stake it does not hold in Shanghai-based LaNova Medicines for no more than $950.92 million.
(Reporting by Shivangi Lahiri in Bengaluru; Editing by Mrigank Dhaniwala)
((Shivangi.Lahiri@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.